business

Merck's strong third-quarter performance, driven by robust sales of its immunotherapy Keytruda and its new injectable form, has led the company to raise its profit outlook and refine its revenue guidance, signaling positive momentum as it prepares for future challenges from generic competition.

Eli Lilly's upcoming third-quarter earnings report is anticipated to reflect strong performance driven by its obesity and diabetes drugs, particularly Zepbound and Mounjaro, alongside the recent launch of Foundayo.

FedEx's quarterly earnings exceeded Wall Street expectations, prompting the company to raise its full-year outlook, despite a slight decline in share price during after-hours trading. This marks a significant moment as it reflects the company's strategic adjustments and operational improvements.

The Federal Reserve's decision to maintain interest rates at 3.75% to 4% amid rising energy costs highlights ongoing inflation concerns, impacting consumer borrowing costs and household budgets. This stability may lead to potential rate hikes in December as the Fed aims to control inflation.

Investors are being advised that now may be an opportune time to purchase corporate bonds, particularly from highly rated companies, as yields remain attractive amidst a stable interest rate environment. This situation is seen as a unique chance to invest in high-quality debt at favorable yields, especially from major tech firms involved in AI projects.

Ford Motor's upcoming third-quarter earnings report is anticipated to show a decline in revenue and adjusted earnings per share, raising concerns among investors about the impact of production disruptions on its key F-150 model.